AU4542893A - Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine - Google Patents
Methods and compositions for treating depression and other disorders using optically pure (-) sibutramineInfo
- Publication number
- AU4542893A AU4542893A AU45428/93A AU4542893A AU4542893A AU 4542893 A AU4542893 A AU 4542893A AU 45428/93 A AU45428/93 A AU 45428/93A AU 4542893 A AU4542893 A AU 4542893A AU 4542893 A AU4542893 A AU 4542893A
- Authority
- AU
- Australia
- Prior art keywords
- sibutramine
- amount
- pharmaceutically acceptable
- human
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU45298/97A AU721924B2 (en) | 1992-06-23 | 1997-11-21 | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90304092A | 1992-06-23 | 1992-06-23 | |
US903040 | 1992-06-23 | ||
PCT/US1993/005966 WO1994000114A1 (fr) | 1992-06-23 | 1993-06-22 | Procedes et compositions utilises pour traiter la depression et d'autres affections avec de la sibutramine (-) optiquement pure |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU45298/97A Division AU721924B2 (en) | 1992-06-23 | 1997-11-21 | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4542893A true AU4542893A (en) | 1994-01-24 |
Family
ID=25416838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU45428/93A Abandoned AU4542893A (en) | 1992-06-23 | 1993-06-22 | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0647134A4 (fr) |
JP (1) | JPH08500093A (fr) |
AU (1) | AU4542893A (fr) |
CA (1) | CA2138998A1 (fr) |
WO (1) | WO1994000114A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020006963A1 (en) * | 1992-06-23 | 2002-01-17 | Young James W. | Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compounds |
GB9402641D0 (en) * | 1994-02-11 | 1994-04-06 | Boots Co Plc | Therapeutic agents |
US5676967A (en) * | 1995-04-18 | 1997-10-14 | Brennen Medical, Inc. | Mesh matrix wound dressing |
DE19518988A1 (de) * | 1995-05-29 | 1996-12-05 | Basf Ag | Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit |
GB9619962D0 (en) * | 1996-09-25 | 1996-11-13 | Knoll Ag | Medical treatment |
US6476078B2 (en) | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
US6974838B2 (en) | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
US6339106B1 (en) | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
US6046242A (en) * | 1998-11-27 | 2000-04-04 | Basf Aktiengesellschaft | Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence |
US6342533B1 (en) | 1998-12-01 | 2002-01-29 | Sepracor, Inc. | Derivatives of (−)-venlafaxine and methods of preparing and using the same |
US6197828B1 (en) | 1998-12-01 | 2001-03-06 | Sepracor, Inc. | Derivatives of (+)-venlafaxine and methods of preparing and using the same |
US6696495B2 (en) | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
US6323242B1 (en) | 1998-12-02 | 2001-11-27 | Peter Sterling Mueller | Treatment of disorders secondary to organic impairments |
TR200102699T2 (tr) * | 1999-03-19 | 2002-03-21 | Knoll Gmbh | Kronik mafsal bozukluĞunun (osteoarthritis) tedavisi |
PL350924A1 (en) | 1999-04-06 | 2003-02-10 | Sepracor Inc | Derivatives of venlafaxine and methods of preparing and using the same |
US6399826B1 (en) | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
US20020115727A1 (en) * | 2000-12-04 | 2002-08-22 | Senanayake Chris H. | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
ES2290281T5 (es) | 2001-02-12 | 2017-09-11 | Wyeth Llc | Sal de succinato de O-desmetil-venlafaxina |
WO2002083631A1 (fr) | 2001-04-13 | 2002-10-24 | Sepracor Inc. | Procedes permettant la preparation de didesmethylsibutramine et d'autres derives de sibutramine |
US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
JP2005523334A (ja) * | 2002-04-24 | 2005-08-04 | サイプレス バイオサイエンス, インコーポレイテッド | ストレス関連障害を含む機能的身体障害の予防および処置 |
CN1671368A (zh) * | 2002-07-24 | 2005-09-21 | 柏树生物科学公司 | 疼痛继发性抑郁(dsp)的治疗 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3008993A1 (de) * | 1980-03-08 | 1981-10-01 | Röhm Pharma GmbH, 6100 Darmstadt | Pharmazeutische zubereitungen |
IE52768B1 (en) * | 1981-04-06 | 1988-02-17 | Boots Co Ltd | 1-arylcyclobutylalkylamine compounds useful as therapeutic agents |
ZA821577B (en) * | 1981-04-06 | 1983-03-30 | Boots Co Plc | Therapeutic agents |
GB8531071D0 (en) * | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
JP2675573B2 (ja) * | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
IE61928B1 (en) * | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
US5104899A (en) * | 1990-08-13 | 1992-04-14 | Sepracor, Inc. | Methods and compositions for treating depression using optically pure fluoxetine |
-
1993
- 1993-06-22 AU AU45428/93A patent/AU4542893A/en not_active Abandoned
- 1993-06-22 WO PCT/US1993/005966 patent/WO1994000114A1/fr not_active Application Discontinuation
- 1993-06-22 CA CA002138998A patent/CA2138998A1/fr not_active Abandoned
- 1993-06-22 JP JP6502536A patent/JPH08500093A/ja active Pending
- 1993-06-22 EP EP93915448A patent/EP0647134A4/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JPH08500093A (ja) | 1996-01-09 |
CA2138998A1 (fr) | 1994-01-06 |
WO1994000114A1 (fr) | 1994-01-06 |
EP0647134A1 (fr) | 1995-04-12 |
EP0647134A4 (fr) | 1997-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4542893A (en) | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine | |
US6110973A (en) | Methods for treating obesity and weight gain using optically pure (-)-bupropion | |
AU4542993A (en) | Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine | |
US5648396A (en) | Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor | |
RU2001614C1 (ru) | R (+)-N-Пропаргил-1-аминоиндан и его фармацевтически пригодные кислотно-аддитивные соли и фармацевтическа композици , обладающа ингибирующей B-форму фермента моноаминооксидазы активностью | |
TWI298255B (en) | Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder | |
US20020006964A1 (en) | Methods of using and compositions comprising (+) sibutramine optionally in combination with other pharmacologically active compounds | |
JP2003501344A (ja) | (+)−ベンラファキシン誘導体並びにその製造方法および使用方法 | |
JP2013256526A (ja) | (−)−ベンラファキシン誘導体並びにその製造方法および使用方法 | |
EP1904066B1 (fr) | COMBINAISONS D'ESZOPICLONE ET DE TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPHTALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTALENAMINE, pour le TRAITEMENT DE LA MENOPAUSE, perimenopause ET des TROUBLES COGNITIFS | |
EP0687472A2 (fr) | Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A | |
CZ20013607A3 (cs) | Farmaceutický prostředek | |
DE69607904T2 (de) | Potenzierung von Serotonin-Wirkstoffresponz | |
US4690949A (en) | Therapeutic drug for dementia | |
CA2318960A1 (fr) | Utilisations pharmaceutiques de (+)-bupropion optiquement pur | |
JP2004501130A (ja) | 5−ht3受容体及び神経細胞のニコチン性受容体に対するアンタゴニストとしての1−アミノ−アルキルシクロヘキサン | |
WO2002060428A2 (fr) | Modes d'utilisation et compositions comprenant de la (-) sibutramine, eventuellement combinee a d'autres composes pharmaceutiquement actifs | |
AU721924B2 (en) | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine | |
US5492933A (en) | Methods and compositions for treating urinary incontinence and other disorders using optically pure R-terodiline and hydroxylated derivatives thereof | |
WO1992013452A1 (fr) | Procedes d'utilisation et compositions de r(-) fluoxetine | |
US4141993A (en) | Compounds of diphenylcyclopentylamine type and methods for their preparation | |
WO1995010270A1 (fr) | Procedes de traitement de l'incontinence urinaire a l'aide de terodiline optiquement pure |